Corrigendum to “Multistimuli-responsive PEGylated polymeric bioconjugate-based nano-aggregate for cancer therapy” [Chem. Eng. J. 391 (2020) 123543]

Lactate Efflux Inhibition by Syrosingopine/LOD Co‐Loaded Nanozyme for Synergetic Self‐Replenishing Catalytic Cancer Therapy and Immune Microenvironment Remodeling

“…Utmost separation of the red and green fluorescent signal observed after 4 h of incubation (as shown in Figure 2D) indicated that the nanoparticles transported to the cellular plasma via endocytosis and lysosomal escape. [ 32 ] Subsequently, Mander's overlap coefficients (MOC) were calculated using the Image J software to quantify the lysosomal localization of three kinds of nanoparticles (Figure S10B, Supporting Information). The results showed that with an extension of the incubation time of the B16‐F10 cells and nanoparticles, more nanoparticles escaped from the lysosomes into the cytoplasm, and the MOC value decreased.…”

“…The possible reason was that the LOD@HFN and Syr/LOD@HFN could catalyze the production of H 2 O 2 from the lactic acid, which damaged the lysosome and achieved a more efficient lysosomal escape. [ 32 ]…”

“…The possible reason was that the LOD@HFN and Syr/LOD@HFN could catalyze the production of H 2 O 2 from the lactic acid, which damaged the lysosome and achieved a more efficient lysosomal escape. [32] To further assess the inhibition efficiency of lactate efflux by the Syr, the amount of intracellular and extracellular lactate was measured. After 6 h of free Syr treatment, lactate secretion was reduced by 45.6% in the B16-F10 cells, whereas it was reduced by only 25.9% and 13.8% in the cells treated with the MCT1 inhibitor AZD3965 or the MCT4 inhibitor VB124 alone, respectively (Figure 2E).…”